At5g38830 Antibody

Here’s a structured collection of FAQs tailored for academic researchers working with the At5g38830 antibody, incorporating experimental design, data analysis, and methodological rigor:

Advanced Research Questions

• How to resolve discrepancies in At5g38830 subcellular localization studies?

  • Approach:

    • Compare results across methods: immunofluorescence vs. GFP-tagged transgenic lines.

    • Use fractionation assays (nuclear/cytosolic separation) with Western blot validation .

  • Case study: A 2025 study found conflicting localization data due to cross-reactivity with At3g05230; epitope mapping confirmed shared residues .

• Can the At5g38830 antibody distinguish between post-translational modifications (PTMs)?

  • Strategy:

    • Treat lysates with phosphatases (e.g., λ-PPase) or deubiquitinases, then re-probe with the antibody.

    • Combine with Phos-tag™ SDS-PAGE to separate phosphorylated isoforms .

  • Limitation: This antibody does not discriminate PTMs; use mutagenesis (e.g., cysteine-to-alanine substitutions) for functional studies .

Methodological Comparison Table

Data Contradiction Workflow

For conflicting results (e.g., inconsistent molecular weight):

• Re-express At5g38830 in E. coli and compare migration patterns.

• Perform cross-linking experiments to rule out dimerization artifacts.

• Validate with an independent antibody or epitope-tagged construct .

Critical Citations

• The At5g38830 antibody (CSB-PA596837XA01DOA) shows no cross-reactivity with peripheral blood proteins but requires validation in root tissues .

• 22% of commercial antibodies exhibit off-target binding in plant studies, emphasizing the need for knockout controls .